Updates From Maximon - September

Read our monthly newsletter.

Updates From Maximon - August

Read our monthly newsletter.

Investments in anti-aging: In longevity the new big businesses of the billionaires

Longevity and Maximon are featured on Protothema, the biggest Greek news site

Updates From Maximon - July

Read our monthly newsletter.

Avea secured $5M to accelerate its growth

Maximon venture Avea Life has successfully closed a funding round by raising an impressive $5 million. With this significant boost, Avea Life is set to accelerate its growth across Europe and establish its presence in the APAC market.

Updates From Maximon - June

Read our monthly newsletter.

Maximon increases investment volume for Longevity start-ups to CHF 30 million and enlarges its Board of Directors

Maximon - The Company Builder is providing additional capital for the construction of Longevity companies. In addition, the Board of Directors will be further reinforced with Christoph Schwarzenbach.

Updates From Maximon - May

Read our monthly newsletter.

Biolytica secured CHF 5.25 million in funding from Maximon

Maximon fully supports Biolytica on their mission to build out personalised health accessible to everyone. Their innovative approach to healthcare is paving the way for a brighter, more inclusive future.

Updates From Maximon - March & April

Read our monthly newsletter.

Maximon Longevity Prize Applications are Open!

Maximon's Longevity Prize 2023 is now accepting applications for translational longevity research projects! If you have an innovative idea that can help extend the human lifespan, we want to hear from you.

Longevity is near – and what you can do with it | Tobias Reichmuth | TEDxBielBienne

Tobias Reichmuth explores the concept of longevity, discussing how our increasing lifespan presents both challenges and opportunities for society. He offers insights into the latest scientific and technological advancements in anti-aging research and how they could transform the way we live our lives.

Marc P. Bernegger on the emerging field of longevity

Marc P. Bernegger explains how longevity has been transformed from a futurist niche to a scientifically backed Megatrend and how with his latest endeavour, Maximon, he's is capitalizing it.

Updates from Maximon - February

Read our monthly newsletter.

Traum vom langen Leben: Start-ups wollen Schweiz zum Hotspot des Trends machen

Immer mehr Healthtech-Firmen zieht es in die Schweiz. Der gute Zugang zu Kunden und Kapital hilft Firmen, auch in Deutschland zu expandieren.

Forever Young

„Forever Young“: Tech elite and venture capitalists have declared war on death. Thanks to billions invested in promising research results, mankind's greatest dream, eternal life, seems more tangible than ever.

Länger Gesünder Leben

Longer Healthier Life: Read the Transkript article from the authors Georg Kääb and Gwendolyn Dorow about longevity, life extension, rejuvenation and how it is not a field just for esoterics anymore, as more and more investors are getting involved.

Updates from Maximon - January

Read our monthly newsletter for the month of January.

Longevity sector focus at Davos

Longevity remains key focus at World Economic Forum 2023.

Longevity takes over Davos (again)

Longevity stays in the limelight on the streets of Davos for the second time during this year’s World Economic Forum (WEF). The world is growing – and aging – at a rapid rate, and nearly a third of the world’s population will be over 60 years old by 2050.

Updates from Maximon - December

Read our monthly newsletter.

Updates from Maximon - November

Read our monthly newsletter.

Inside the billion-dollar meeting for the mega-rich who want to live forever

Hope, hype, and self-experimentation collided at an exclusive conference for ultra-rich investors who want to extend their lives past 100. I went along for the ride.

Tobias Reichmuth – the longevity market starts now

Dr Tobias Reichmuth talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research.

Updates from Maximon

Read our monthly newsletter.

Meet the company builders that think they can reverse ageing

Longevity research has often focused on combatting one specific aspect of ageing, like regenerating the liver or the brain. But recently, there’s been a shift towards looking for the silver bullet for all age-related diseases.

‘We want to bring the concept of longevity to life’

Maximon CSO talks clinics, diagnostics, and why longevity is about much more than drug development.

Can we find ways to live beyond 100? Millionaires are betting on it.

At a luxury resort in the Swiss Alps, wealthy investors and scientists are cooking up plans to push the limits of the human lifespan.

Eye-level longevity – why breakthrough research is top investment opportunity

Our pioneers of longevity discuss where the field can be monetised and the breadth of the total addressable market.

Updates from Maximon - August

Read our monthly newsletter for the month of August.

Datenanalysen und langes Leben

Handelszeitung published an interesting story about extending the human lifespan mentioning Maximon, Avea Life, Biolytica and our future longevity ventures.

Elisabeth Roider joins Maximon as a Partner & Chief Scientific and Medical Officer

Driven by the mission to identify and solve the most relevant medical and public health problems, Elisabeth Roider joins Maximon as a Partner & Chief Scientific and Medical Officer.

Updates from Maximon - July

Read our monthly newsletter for the month of July.

Updates from Maximon - June

Read our monthly newsletter for the month of June.

Updates from Maximon - May

Read our monthly newsletter for the month of May.

Longevity takes over Davos – and has Gstaad in its sights

Longevity was one of the most talked about industries on the streets of Davos during this year’s World Economic Forum (WEF), one of the largest gatherings of the world’s financial and political elite.

AVEA included in the “Startups to watch in the DACH Region” list by Sifted

AVEA was included in the “Startups to watch in the DACH Region” list by Sifted.

CHF2.5 million to support the growth of longevity start-up AVEA

Our first longevity venture, Avea Life, announces the closing of a 2.5 million CHF seed financing round.

Updates from Maximon - April

Read our monthly newsletter for the month of April

Ten simple rules for building a successful science start-up

A peer-reviewed publication with a mix of thoughts and experiences from our Founding Partner Dr. Tobias Reichmuth and our Scientific Advisor Prof. Dr. Collin Y. Ewald.

Updates from Maximon - March

Read our monthly newsletter for the month of March.

New innovation longevity research prize launched

The most innovative longevity research could bag 50k CHF thanks to Maximon, which is launching its first Prize for Translational Research in Longevity.

Longevity: Der HealthTech Trend, auf den der Company Builder Maximon setzt

Wer ein neues Schlagwort in der HealthTech-Branche sucht, wird bei Longevity fündig. Kleine wie große Unternehmen suchen verstärkt nach Medikamenten, Therapien und digitalen Mitteln, um die Langlebigkeit von Menschen in überalterten Gesellschaften wie Europa oder Japan zu verbessern.
Mit Maximon, gegründet von den Schweizer Unternehmern Tobias Reichmuth und Marc Bernegger, gibt es einen neuen Company Builder, der auf Longevity-Startups setzt.

European investors have a new obsession: longevity

Imagine a world where the average life expectancy is well over 100 years (and doesn’t involve spending 30 years in a care home). Imagine a world where — thanks to scientific findings made over the last five years — there’s a cure for ageing.

Sophie Chabloz darüber, welche Stoffe das Altern bremsen können

Die Gesundheitswissenschafterin Sophie Chabloz über Nahrungsergänzungsmittel, die verjüngen können. Sie erzählt, was sie selber nimmt und wie es wirkt.

Maximon launches 100 million Longevity Co-Investment Fund

The Longevity Co-Investment Fund finances longevity-focussed start-up companies launched by company-builder Maximon.

First companies benefit from Maximon's Longevity Co-Investment Fund

The newly launched CHF 100 million Fund finances longevity-focussed start-ups founded by Swiss company builder Maximon. The Fund’s first investments include Zug based companies AVEA and Biolytica.

Tobias Reichmuth, Mitgründer Maximon, im Interview

Herr Reichmuth, Longevity, oder Langlebigkeit, tönt ein wenig nach der Suche des heiligen Grals, dem Wunsch, ewig jung zu sein. Wollen Sie das ewige Leben ermöglichen?

The Rising Importance of Crypto in Aging Research

The cryptocurrency world is colliding with aging research and life extension and could change how research gets funded.

Maximon gründet den weltweit ersten Longevity Company Builder

Zug – Maximon ist ein neuer Company Builder mit Sitz in der Schweiz, der das Ziel verfolgt, den “Health-Span”, also die Zeitspanne ohne Altersleiden und Krankheiten, zu verlängern und Menschen eine fitte, gesunde und glückliche Langlebigkeit zu ermöglichen.

Can finance give Old Father Time a run for his money?

It looks like longevity is in it for the long run in Switzerland. Financiers are serious about funding the science of longer and healthier lives. The Swiss “Longevity Valley” dream also has political backing.

Serial Entrepreneurs gründen Company Builder mit Fokus auf Langlebigkei

Maximon soll in den kommenden Jahren systematisch Startups hervorbringen, deren Produkte die Zeitspanne ohne Altersleiden und Krankheiten verlängern. Das vierköpfige Gründungsteam hat bereits Millionen investiert und arbeitet an ersten Projekten.

Maximon builds new longevity companies from scratch

“The real difference is that we really build the companies from scratch,” - Tobias Reichmuth, co-founder of Maximon.

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice.

The economic value of targeting aging

A recent paper written by economist Martin Ellison of Oxford University. biologist David Sinclair of Harvard Medical School, and economist Andrew Scott from London Business School, calculates that an intervention that successfully slows down biological aging—lowering mortality and frailty at each age, such that U.S. life expectancy would increase by just one year—is estimated to be worth $37 trillion in net present value terms. That’s the equivalent of around $700 billion annually, more than 3 percent of the country’s entire GDP.

Avea secured $5M to accelerate its growth

Maximon venture Avea Life has successfully closed a funding round by raising an impressive $5 million. With this significant boost, Avea Life is set to accelerate its growth across Europe and establish its presence in the APAC market.

Updates From Maximon - September

Read our monthly newsletter.